Charles Fuchs, MD, MPHEnriched profile
Chief Medical Officer, Tubulis GmbH (appointed January 8, 2026; based in Tubulis' U.S. Cambridge, MA office); immediately prior: Senior Vice President and Global Head of Oncology & Hematology Product Development, Genentech and Roche (2021-Jan 2026) · Yale Cancer Center
Overview
Updated 14 Jul 2026
Charles S. Fuchs is Chief Medical Officer, Tubulis GmbH (appointed January 8, 2026. The public record shows 1,721 publications with 114,486 citations (h-index 172), centered on Colorectal Cancer Treatments and Studies, Pancreatic and Hepatic Oncology Research, Gastric Cancer Management and Outcomes. It also documents an investigator role on 7 registered clinical trials, 5 NIH-funded awards (2016–2022).
- Most recent indexed publication: 2026 · Cancer immunology research
- Top research focus: Colorectal Cancer Treatments and Studies
- 7 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 764.
Clinical & industrytrials, payments and federal funding
Not shown. No U.S. clinical registration on file.
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 2CompletedNCT00409292 - Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 1CompletedNCT00251407 - Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 1CompletedNCT00251355
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
Updated 14 Jul 2026
5 NIH research awards on record, funded 2016–2022 per NIH RePORTER. The latest:
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- T-cell Subset Features and Distributions Evolve across the Colorectal Precancer-Cancer Spectrum.
Cancer immunology research
2026 - Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival.
Cancer epidemiology, biomarkers & prevention
2023 - Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization.
Cancer epidemiology, biomarkers & prevention
2023
Most-cited worksby citation count (OpenAlex)
Contact
No public contact details on file. Research profiles have no U.S. clinical registration, so there's no federal registry record to draw an address or phone from. Why? →
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
- Internal medicine residency (chief medical resident)
Brigham and Women's Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗ - Medical oncology fellowship
Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
- Former Chief
Gastrointestinal Oncology Division, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Awards & honorshonors on the public record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cytomx.com ↗
- Giants of Cancer Care award
Gastrointestinal Cancer category (2017), OncLive/Giants of Cancer Care program
2017verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗ - Robert T. and Judith B. Hale Chair in Pancreatic Cancer
Dana-Farber Cancer Institute (endowed chair, former role)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cytomx.com ↗
Secondary affiliationsappointments beyond the home institution
- Former Senior Vice President and Global Head of Oncology & Hematology Product Development
Genentech and Roche
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →endpoints.news ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.yale.edu ↗
- Founder & Director
EvolveImmune Therapeutics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →endpoints.news ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fiercebiotech.com ↗
- Author (with Abbe Gluck)
"A New Deal for Cancer: Lessons from a 50 Year War" (book, Hachette/PublicAffairs, 2021); discussed on Becker's Hospital Review podcast
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →beckershospitalreview.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/charles-fuchs-md-2203d6ea
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Doximity
doximity.com/pub/charles-fuchs-md-3baa7c8f
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/charles-fuchs-14391a14
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by otherswhere others cite or feature them
- Facebook
facebook.com/SmilowCancerHospital/videos/dr-charles-fuchs-director-of-yale-cancer-center-and-physician-in-chief-of-smilow/715800245841445
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
medicine.yale.edu/media-player/dr-charles-fuchs-discusses-approval-of-pembrolizumab-for-stomach-cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Other
medicine.yale.edu/media-player/dr-charles-fuchs-profile
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Winer, MD
Yale Cancer Center
- 1,624
- publications
- 171
- h-index
- 20
- trials
Roy Herbst, MD, PhD
Yale Cancer Center
- 1,336
- publications
- 135
- h-index
- 8
- trials
Mario Sznol, MD
Yale Cancer Center
- 536
- publications
- 92
- h-index
- 18
- trials
Patricia Lorusso, DO
Yale Cancer Center
- 1,281
- publications
- 86
- h-index
- 31
- trials